Progressive multifocal leukoencephalopathy associated with obinutuzumab–bendamustine: combination therapy with mirtazapine and immunoglobulin

Progressive multifocal leukoencephalopathy (PML) is a severe opportunistic infection of the central nervous system resulting from JC virus (JCV) reactivation, often leading to substantial neurological morbidity and mortality. While associated with various immunotherapies, the incidence of PML specifically following obinutuzumab-bendamustine as first-line therapy remains under-reported. We aim to highlight this potent regimen as a trigger for JCV reactivation and evaluate therapeutic strategies. We describe a patient who presented with cognitive decline two years after completing obinutuzumab-bendamustine therapy for follicular lymphoma, accompanied with profound lymphopenia and hypogammaglobulinemia. A diagnosis of PML was established based on deep white matter lesions on brain MRI and a positive cerebrospinal fluid (CSF) polymerase chain reaction for JCV. Treatment consisted of daily mirtazapine together with intravenous immunoglobulin (IVIG) supplementation. At the 2-year follow-up, the patient demonstrated sustained radiological stabilization, cognitive improvement, and undetectable JCV viral load in CSF. Obinutuzumab-bendamustine therapy represents a distinct clinical trigger for PML due to its dual-arm immunosuppressive effects on humoral and cellular immunity. While endogenous cellular immune restoration likely played a primary role in viral clearance, adjunctive mirtazapine and IVIG may represent a feasible supportive strategy, particularly following B-cell-depleting therapy. The therapeutic contribution of this combined regimen requires further investigation.

Authors

Institutions

Publication Details

Journal
Immunological Medicine
Published
2026-11-12
DOI
https://doi.org/10.1080/25785826.2026.2760587
Primary Topic
Polyomavirus and related diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Progressive multifocal leukoencephalopathy associated with obinutuzumab–bendamustine: combination therapy with mirtazapine and immunoglobulin

Junichi Miyahara, Yohei Takenobu, Kazuo Nakamichi, Manabu Inoue et al.
Immunological Medicine
Polyomavirus and related diseases
article

Progressive multifocal leukoencephalopathy associated with obinutuzumab–bendamustine: combination therapy with mirtazapine and immunoglobulin

Junichi Miyahara, Yohei Takenobu, Kazuo Nakamichi, Manabu Inoue, Mari Inoue, Kazuki Yukawa, Yuki Hama, Mizuha Toyama, Karen Hatano, Keita Mochida, Kentaro Yamakawa
article en

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe opportunistic infection of the central nervous system resulting from JC virus (JCV) reactivation, often leading to substantial neurological morbidity and mortality. While associated with various immunotherapies, the incidence of PML specifically following obinutuzumab-bendamustine as first-line therapy remains under-reported. We aim to highlight this potent regimen as a trigger for JCV reactivation and evaluate therapeutic strategies. We describe a patient who presented with cognitive decline two years after completing obinutuzumab-bendamustine therapy for follicular lymphoma, accompanied with profound lymphopenia and hypogammaglobulinemia. A diagnosis of PML was established based on deep white matter lesions on brain MRI and a positive cerebrospinal fluid (CSF) polymerase chain reaction for JCV. Treatment consisted of daily mirtazapine together with intravenous immunoglobulin (IVIG) supplementation. At the 2-year follow-up, the patient demonstrated sustained radiological stabilization, cognitive improvement, and undetectable JCV viral load in CSF. Obinutuzumab-bendamustine therapy represents a distinct clinical trigger for PML due to its dual-arm immunosuppressive effects on humoral and cellular immunity. While endogenous cellular immune restoration likely played a primary role in viral clearance, adjunctive mirtazapine and IVIG may represent a feasible supportive strategy, particularly following B-cell-depleting therapy. The therapeutic contribution of this combined regimen requires further investigation.

Immunological Medicine
Kyoto University (JP), National Institute of Infectious Diseases (JP), Osaka Red Cross Hospital (JP), Japan Institute for Health Security (JP)
Ministry of Health, Labour and Welfare
Good health and well-being
Polyomavirus and related diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon